

Proactive Group

16:55 25 Feb 2019

Baird 'more cautious' on Karyopharm Therapeutics getting quick FDA approval for cancer drug selinexor

Baird analysts saw slimmer chances of Karyopharm Therapeutics Inc (NASDAQ:KPTI) getting accelerated approval for its new cancer drug selinexor aimed at treating multiple myeloma.

On Friday, the Food and Drug Administration released disappointing selinexor briefing documents highlighting "limited efficacy and significant toxicity."

Shares in the Newton, Massachusetts, pharma company nosedived Friday after the FDA briefing documents were released but recovered some ground Monday, rising 5.5% to \$5.30 in morning trade.

READ: Humanigen study of monoclonal antibody in CAR-T therapy presented at Houston conference

"As such, we are more cautious on accelerated approval in triple class-refractory multiple myeloma and await clarity from the Oncologic Drugs Advisory Committee (ODAC) panel (February 26)," wrote Baird analysts Michael E Ulz and Colleen M Hanley to clients in a note over the weekend.

"However, based on the draft questions, the FDA seems to suggest waiting for data from the randomized, Phase 3 BOSTON study (2L+: SVd vs. Vd) YE19 as a potential option, which could address many concerns, in our view," they added.

The analysts at Baird maintained an Outperform rating on Karyopharm Therapeutics shares.

"Though we expect near-term volatility, given potential for approval, we maintain our Outperform rating," wrote the analysts. "Overall, at current levels, limited value is being assigned to selinexor (cash: approximately \$3/share) even in the more meaningful 2L+ population and any signs of positive developments could drive upside."

Status of New Drug Application

Karyopharm Therapeutics submitted a new drug application for a combination of selinexor and dexamethasone that is being evaluated for penta-refractory multiple myeloma. Selinexor functions by binding with and inhibiting the nuclear export protein XPO1, resulting in the accumulation of tumor suppressor proteins in the cell nucleus.

The new drug application (NDA) was made based on Part 2 of the Phase 2b trial dubbed STORM. The FDA accepted the application on October 5, according it Priority Review status, cutting the review period to six months.

However, the FDA's concerns highlighted on Friday have dampened expectations linked to speedy approval.

"The FDA highlighted selinexor's toxicity profile, indicating 60.2% of Part 2 STORM patients experienced a serious adverse event, 88.6% required dose modification due to a treatment emergent adverse events (TEAE) and 28.5% discontinued due to a TEAE," wrote the analysts.

Share Information

Code: PROAC

Listing: PRIVATE-UK

Sector: Media

Website: www.proactiveinvestors.co.uk

Company Synopsis:

Proactiveinvestors is a leading multi-media news organisation, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt and London. Proactiveinvestors operates five financial websites in four languages providing breaking news, comment and analysis on hundreds of listed companies across the globe daily. We are one of the fastest growing financial media portals in the world.

action@proactiveinvestors.com

Additionally, 23 deaths occurred within 30 days of study treatment, and the FDA indicated 10 were due to treatment emergent adverse events, although only two of these were assessed as related to selinexor by the investigator, said the analysts.

"The FDA also used data from a prior study in acute myeloid leukemia (development discontinued) to highlight toxicity, where selinexor resulted in a worsening trend on overall survival compared to physician's choice (HR=1.18). Overall, given selinexor's safety profile, we are not surprised by the FDA's focus on toxicity," wrote the analysts.

The FDA's Oncologic Drugs Advisory Committee is set to discuss the NDA at a meeting on Tuesday, February 26.

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.